Predictors of warfarin non-adherence in younger adults after valve replacement surgery in the South Pacific
- PMID: 27347009
- PMCID: PMC4916564
- DOI: 10.1136/heartasia-2016-010751
Predictors of warfarin non-adherence in younger adults after valve replacement surgery in the South Pacific
Abstract
Objectives: Globally, mechanical valves are predominant as replacements for adolescents and younger adults with rheumatic heart disease (RHD). Mechanical valve implantation necessitates lifelong antithrombotic management (warfarin) and associated lifestyle modification, with event-free survival largely dependent on international normalised therapeutic ratios (INRs) remaining within the target therapeutic range. There is limited information on factors that may influence warfarin adherence among younger people or those in resource-limited settings. This study sought to identify predictors of warfarin adherence after valve replacement surgery for RHD in Fiji (n=127).
Methods: A cross-sectional study design was used.
Results: The sample had a mean age of 31.23 years (SD 13.34) and a mean time-since-surgery of 3.72 years (SD 3.95). Just over half were women (n=71, 56%) and almost two-thirds were indigenous (I-taukei, n=78, 61%). Most had an isolated valve procedure (n=94, 74%) and at the time of survey, they were in New York Heart Association Class I (n=97, 76%). A quarter (n=33, 26%) reported poor adherence with anticoagulation therapy and 13.38% (n=17) reported complete warfarin cessation. While younger age was significantly associated with non-adherence to warfarin therapy (p=0.008), the independent predictors of people who discontinue warfarin completely were those not understanding why warfarin was needed (OR=9.97, p=0.006); a history of forgetting to take warfarin (OR=8.64, p=0.0013) and travel time to heart clinic >1 hour (OR=5.80, p=0.039).
Conclusions: While medication adherence is complex and multifactorial, the consequences of warfarin non-adherence are potentially catastrophic. These results provide an important first step towards the development of country-specific and disease-specific strategies to improve warfarin adherence.
Keywords: VALVULAR DISEASE.
References
-
- Carapetis J, Brown A, Walsh W et al. . Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia. An evidence-based review. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, 2006.
-
- World Health Organization. WHO expert consultation on rheumatic fever and rheumatic heart disease. WHO technical report series: 923 Geneva, Switzerland: World Health Organization, 2004.
-
- Zühlke L, Engel ME, Karthikeyan G et al. . Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015;36:1115–22. doi:10.1093/eurheartj/ehu449 - DOI - PMC - PubMed
-
- Singh PIPK, Carapetis JR, Buadromo EM et al. . The high burden of rheumatic heart disease found on autopsy in Fiji. Cardiol Young 2008;18:62–9. doi:10.1017/S1047951107001734 - DOI - PubMed
-
- Nishimura RA, Otto CM, Bonow RO et al. . 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2438–88. doi:10.1016/j.jacc.2014.02.537 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources